Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,395 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants.
Egbuna O, Zimmerman B, Manos G, Fortier A, Chirieac MC, Dakin LA, Friedman DJ, Bramham K, Campbell K, Knebelmann B, Barisoni L, Falk RJ, Gipson DS, Lipkowitz MS, Ojo A, Bunnage ME, Pollak MR, Altshuler D, Chertow GM; VX19-147-101 Study Group. Egbuna O, et al. Among authors: campbell k. N Engl J Med. 2023 Mar 16;388(11):969-979. doi: 10.1056/NEJMoa2202396. N Engl J Med. 2023. PMID: 36920755 Clinical Trial.
Abatacept in B7-1-positive proteinuric kidney disease.
Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW 3rd, Mundel P. Yu CC, et al. N Engl J Med. 2013 Dec 19;369(25):2416-23. doi: 10.1056/NEJMoa1304572. Epub 2013 Nov 8. N Engl J Med. 2013. PMID: 24206430 Free PMC article.
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.
Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, Lieberman K, Marder B, Meyers KE, Mustafa E, Radhakrishnan J, Srivastava T, Stepanians M, Tesar V, Zhdanova O, Komers R; DUET Study Group. Trachtman H, et al. Among authors: campbell kn. J Am Soc Nephrol. 2018 Nov;29(11):2745-2754. doi: 10.1681/ASN.2018010091. J Am Soc Nephrol. 2018. PMID: 30361325 Free PMC article. Clinical Trial.
Targeting the Endothelin A Receptor in IgA Nephropathy.
Kohan DE, Barratt J, Heerspink HJL, Campbell KN, Camargo M, Ogbaa I, Haile-Meskale R, Rizk DV, King A. Kohan DE, et al. Kidney Int Rep. 2023 Aug 4;8(11):2198-2210. doi: 10.1016/j.ekir.2023.07.023. eCollection 2023 Nov. Kidney Int Rep. 2023. PMID: 38025243 Free PMC article. Review.
The Impact of Histologic Variants on FSGS Outcomes.
Meliambro K, Schwartzman M, Cravedi P, Campbell KN. Meliambro K, et al. Among authors: campbell kn. Int Sch Res Notices. 2014 Oct 29;2014:913690. doi: 10.1155/2014/913690. eCollection 2014. Int Sch Res Notices. 2014. PMID: 27437509 Free PMC article. Review.
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis.
Vincenti F, Fervenza FC, Campbell KN, Diaz M, Gesualdo L, Nelson P, Praga M, Radhakrishnan J, Sellin L, Singh A, Thornley-Brown D, Veronese FV, Accomando B, Engstrand S, Ledbetter S, Lin J, Neylan J, Tumlin J; Focal Segmental Glomerulosclerosis Study Group. Vincenti F, et al. Kidney Int Rep. 2017 Apr 7;2(5):800-810. doi: 10.1016/j.ekir.2017.03.011. eCollection 2017 Sep. Kidney Int Rep. 2017. PMID: 29270487 Free PMC article.
4,395 results